Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84556 trials found · Page 24 of 4228
-
New Two-Pronged attack on aggressive blood cancers
Disease control Not yet recruitingThis is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Experimental cell therapy targets tough autoimmune diseases
Disease control Not yet recruitingThe purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New cell therapy aims to halt aggressive MS in its tracks
Disease control Not yet recruitingThe goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
Four-Drug combo trial aims to wipe out more cancer cells in Tough-to-Treat myeloma
Disease control Not yet recruitingThis is a multicenter, prospective, randomized controlled trial designed to compare the quadruplet regimen of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) with the standard triplet regimen (VRD) in newly diagnosed, transplant-ineligible patients with high-ris…
Phase: PHASE4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
New drug showdown for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton…
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Double-Punch therapy tested for tough leukemia
Disease control Not yet recruitingThis study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Race against time: bringing Hospital-Level heart rescue to the scene
Disease control Recruiting nowOn-scene extracorporeal pulmonary resuscitation (ECPR) for out-of-hospital cardiac arrest (OHCA) seems to speed up the start of extracorporeal membrane oxygenation (ECMO) and shorten low flow during cardiopulmonary resuscitation (CPR) in case of refractory cardiac arrest. The pri…
Phase: NA • Sponsor: University Hospital Ostrava • Aim: Disease control
Last updated Apr 06, 2026 14:17 UTC
-
5-Year quest to halt liver damage in hepatitis b patients
Disease control Not yet recruitingThis study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study cons…
Phase: PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Twice-Yearly HIV prevention shot tested in Real-World south african communities
Prevention Not yet recruitingThe ALIGN study will evaluate the delivery of injectable Lenacapavir (LEN), a long-acting injectable formulation for HIV pre-exposure prophylaxis (PrEP), amongst adolescents and young people (aged 15-35 years) living within the Klipfontein-Mitchell's health sub-district of Cape T…
Sponsor: Desmond Tutu HIV Foundation • Aim: Prevention
Last updated Apr 20, 2026 16:15 UTC
-
Breakthrough drug trial aims to save lives from deadly alcohol hepatitis
Disease control Recruiting nowThe primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater t…
Phase: PHASE3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
New 'Living Drug' trial offers hope for kids with tough cancers
Disease control Recruiting nowThis is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosa…
Phase: PHASE1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
New hope to slow type 1 diabetes? drug trial aims to protect Body's insulin factories
Disease control Recruiting nowPurpose of the Clinical Trial: This clinical trial aims to investigate whether dimethyl fumarate can treat adults with newly diagnosed type 1 diabetes and to evaluate the safety profile of dimethyl fumarate. Primary Research Questions: Does dimethyl fumarate protect pancreatic…
Phase: PHASE3 • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Fast-Made cell therapy tested as potential Game-Changer for tough lupus cases
Disease control Recruiting nowThis is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
First-in-Kids gene editing trial aims to fix rare, dangerous fat disorder
Disease control Recruiting nowThis is a Prospective, Single-center, Open-label, Single-arm Clinical Study to Evaluate the Safety and Efficacy of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Children and Adolescents (4-18 years) With Hyperchylomicronemia
Phase: EARLY_PHASE1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC
-
New hope for young women: tailored cancer treatment aims to save fertility
Disease control Recruiting nowEndometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC p…
Phase: PHASE2, PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Breakthrough trial tests lifesaving treatment for deadly lung crises
Disease control Recruiting nowAcute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events. Inflammation and immune system imbalance are thought to pl…
Phase: PHASE3 • Sponsor: Argyrios Tzouvelekis • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Breakthrough eye cancer drug could save Patients' sight
Disease control Recruiting nowThis is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Phase: PHASE3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New drug trial aims to find best dosing for weight loss
Disease control Recruiting nowThe purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
One-Shot gene therapy trial aims to reset immune system in devastating autoimmune diseases
Disease control Recruiting nowThis is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular RNA encoding the CD19 chimeric antigen receptor (CAR…
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Gene injection trial aims to restore sight in rare blindness disease
Disease control Recruiting nowThe goal of this Clinical trial is to assess the safety and efficacy of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy (LHON)
Phase: PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC